Figure 1

(a) Serous carcinoma of the endometrium (H&E); (b) cytoplasmic expression of IMP3 in serous carcinoma of the endometrium; (c) International Federation of Gynecology and Obstetrics (FIGO) grade 1 endometrioid adenocarcinoma of the endometrium (H&E); (d) negative immunohistochemical stain for IMP3 in FIGO grade 1 endometrioid adenocarcinoma of the endometrium; (e) FIGO grade 3 endometrioid adenocarcinoma of the endometrium (H&E); (f) cytoplasmic expression of IMP3 in FIGO grade 3 endometrioid adenocarcinoma of the endometrium; (g) benign proliferative endometrium (H&E); (h) negative immunohistochemical stain for IMP3 in benign proliferative endometrium.